24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
SUNITCAP 50MG is an Capsules medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | SUNITCAP 50MG |
|---|---|
| Composition | Sunitinib Malate Capsules 50mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Capsules |
| Packaging | Btl (28 tab) |
| Country of Origin | India |
SUNITCAP 50MG (Sunitinib Malate Capsules 50mg) is a widely used Capsules medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
SUNITCAP 50 MG (Sunitinib Malate Capsules 50 mg) is a prescription targeted anticancer medicine containing Sunitinib Malate 50 mg, a potent Tyrosine Kinase Inhibitor (TKI) used in the treatment of various advanced cancers. It works by blocking specific proteins that promote cancer cell growth and the formation of blood vessels that supply nutrients to tumors.
Cancer cells require a continuous blood supply to grow and spread. Sunitinib helps inhibit angiogenesis (the formation of new blood vessels) and interferes with signaling pathways that cancer cells use for survival and proliferation. This targeted mechanism makes it an effective treatment option for several solid tumors.
Unlike traditional chemotherapy, which affects both healthy and cancerous rapidly dividing cells, Sunitinib specifically targets molecular pathways involved in tumor growth, helping to improve treatment outcomes while supporting long-term disease management.
SUNITCAP 50 MG is commonly prescribed for:
The medicine may be used as a first-line treatment or after failure of other therapies, depending on the type and stage of cancer.
Manufactured according to stringent pharmaceutical quality standards, SUNITCAP 50 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Sunitinib therapy require routine monitoring, including blood pressure checks, blood tests, liver function assessments, thyroid evaluations, and regular clinical examinations.
Due to its proven efficacy in multiple cancer types, SUNITCAP 50 MG has become an important treatment option in modern oncology practice.
SUNITCAP 50 MG (Sunitinib Malate Capsules 50 mg) is primarily used in the treatment and management of specific advanced cancers.
The medicine is widely prescribed for advanced and metastatic kidney cancer.
Sunitinib may be used in patients whose GIST has progressed despite previous treatment.
The medicine helps manage certain advanced neuroendocrine tumors of the pancreas.
Doctors may recommend Sunitinib to help slow disease progression in advanced cancers.
The medicine is commonly incorporated into personalized cancer treatment strategies.
Sunitinib supports prolonged disease stabilization and tumor growth suppression.
The medicine targets specific molecular pathways involved in cancer progression.
Sunitinib belongs to a class of medicines known as Tyrosine Kinase Inhibitors (TKIs).
SUNITCAP works by:
This targeted mechanism helps control cancer growth and spread more effectively.
Like all medicines, SUNITCAP 50 MG may cause side effects in some patients. The severity and frequency of side effects vary among individuals.
Weakness and tiredness are frequently reported during treatment.
Blood pressure may increase and require monitoring.
Digestive disturbances may occur during therapy.
Some patients may experience nausea.
Reduced appetite may affect nutritional intake.
Inflammation or ulcers inside the mouth may develop.
Changes in skin color or pigmentation may occur.
Redness, swelling, and discomfort of the hands and feet may develop.
The medicine may affect thyroid hormone levels.
Seek immediate medical attention if you experience:
Patients should contact their healthcare provider immediately if serious symptoms occur.
The dosage of SUNITCAP 50 MG (Sunitinib Malate Capsules 50 mg) should always be determined by a qualified oncologist.
Treatment recommendations vary according to the cancer being treated.
Cancer severity and progression influence therapy planning.
Liver, kidney, heart, and thyroid health may affect dosage decisions.
Doctors may modify therapy according to effectiveness and tolerance.
Drug interactions may require dosage adjustments.
Before starting treatment, inform your doctor if you have:
Patients should also disclose all prescription medications, supplements, vitamins, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant and breastfeeding women should not use this medicine unless specifically advised by a healthcare professional.
It is used for the treatment of advanced kidney cancer, gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors (pNET).
Sunitinib Malate is a targeted anticancer medicine that blocks proteins involved in tumor growth and blood vessel formation.
No. It is a targeted therapy known as a tyrosine kinase inhibitor and works differently from traditional chemotherapy.
Yes. It is widely prescribed for advanced and metastatic renal cell carcinoma.
Yes. High blood pressure is a common side effect and should be monitored regularly.
Yes. Thyroid function changes may occur and require periodic monitoring.
Yes. Blood tests, blood pressure checks, thyroid monitoring, and clinical evaluations are important throughout therapy.
Yes. This medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology and targeted cancer treatment.